Lōkahi's LT-100 Moves Toward Single-Injection Dosing, Clinical Trials Expected Q4 2026
GCTK is trading near its 52-week low of $0.25 (14% above the low) on light trading volume (0.2× avg).
Summary
Lōkahi Therapeutics, Glucotrack's wholly owned subsidiary, is advancing LT-100 toward a single subcutaneous injection per treatment visit, a major simplification from the prior 15 intradermal injections. A Type C meeting with the FDA in May 2026 and a completed nonclinical minipig study support the planned clinical evaluation. The company expects to initiate clinical trials as early as Q4 2026, with initial data in H1 2027. This follows the July 15 reverse merger that gave Lōkahi 90% control of Glucotrack and secured $4.45M in bridge financing. The development progress is a concrete step for the combined entity, which faces going concern doubts and Nasdaq delisting risk. A successful single-injection profile could significantly improve the commercial viability of LT-100.
At the time of this announcement, GCTK was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.25 to $14.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.